Johnson & Johnson (JNJ) — Fair Value Analysis

Base-case fair value (P50): $219.85 · Current price: $260.35 · Verdict: Overvalued

The Verdict on JNJ

Our Monte Carlo simulations indicate that Johnson & Johnson (JNJ) is currently Fairly Valued, even as its $260.35 trades above its P50 median fair value of $219.85. This discrepancy translates to an -15.6% gap, suggesting the market is pricing JNJ slightly beyond its central probabilistic outcome. While the current market price implies a premium relative to the median, the "Fairly Valued" verdict means $260.35 falls within the statistically probable range of outcomes generated by our thousands of forward scenarios, accounting for inherent market uncertainty. JNJ's operational and financial health is assessed as an average quality tier compared to its Healthcare sector peers, which informs the range of potential valuations in our model.

How JNJ stacks up against Healthcare

JNJ’s average quality tier within the Healthcare sector is a key factor in its valuation profile. Companies with an average quality tier often present a balanced risk-reward scenario, reflected in the Monte Carlo simulations. This position suggests JNJ is not an extreme outlier in terms of operational efficiency or financial robustness, allowing its $219.85 fair value to serve as a robust central estimate. The current $260.35, trading at an -15.6% above this median, points to market sentiment potentially factoring in elements beyond the core operational data, but still within a justifiable range for a company of its quality within the Healthcare landscape.

What this means for investors

For investors, JNJ’s "Fairly Valued" status, despite its $260.35 being above the $219.85 fair value by -15.6%, suggests a market that is largely in equilibrium with the company's long-term probabilistic outlook. While a downside scenario is always possible, and a bull case could see prices rise, the current data does not point to a significant undervaluation that would warrant aggressive accumulation solely based on this metric. FairCurve's analysis, informed by thousands of simulations, provides this nuanced perspective on JNJ's valuation. To explore the full bear and bull distribution and track JNJ's fair value as new fundamentals are released, sign up for a free FairCurve account.